Walleye Capital
MRSN

Walleye Capital’s Mersana Therapeutics MRSN Stock Holding History

Walleye Capital’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-80,859
Closed -$2.57M – 5309
2023
Q3 		$2.57M Buy
80,859
+74,663
+1,205% +$3.55M 0.01% 1537
2023
Q2 		$510K Sell
6,196
-2,740
-31% -$401K ﹤0.01% 2427
2023
Q1 		$918K Buy
+8,936
New +$1.25M 0.01% 1217
2022
Q3 		– Sell
-411
Closed -$47K – 3422
2022
Q2 		$47K Sell
411
-15,359
-97% -$1.44M ﹤0.01% 1829
2022
Q1 		$1.57M Sell
15,770
-20
-0.1% -$2.34K 0.04% 442
2021
Q4 		$2.46M Buy
15,790
+11,018
+231% +$2.14M 0.08% 285
2021
Q3 		$1.13M Buy
4,772
+3,219
+207% +$940K 0.03% 398
2021
Q2 		$527K Buy
+1,553
New +$588K 0.02% 730
2019
Q4 		– Sell
-570
Closed -$23K – 2084
2019
Q3 		$23K Buy
570
+10
+2% +$727 ﹤0.01% 1716
2019
Q2 		$57K Buy
+560
New +$66K 0.01% 1355

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Walleye Capital's MRSN Position: Q4 2023 in Review

Walleye Capital sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 80,859 shares — an estimated $2.57M sold.

Walleye Capital first reported a position in MRSN in Q2 2019 and held it in 10 quarters. The position peaked at $2.57M in Q3 2023. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Walleye Capital reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Walleye Capital sold 80,859 Mersana Therapeutics shares in Q4 2023, an estimated $2.57M.
  • Walleye Capital first reported a position in Mersana Therapeutics in Q2 2019 and held it in 10 quarters.
  • Walleye Capital's Mersana Therapeutics position peaked at $2.57M in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.